NASDAQ:INTS Intensity Therapeutics Q4 2025 Earnings Report $4.57 +0.12 (+2.70%) Closing price 07/27/2026 03:59 PM EasternExtended Trading$4.58 +0.01 (+0.22%) As of 07:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Intensity Therapeutics EPS ResultsActual EPS-$0.31Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AIntensity Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AIntensity Therapeutics Announcement DetailsQuarterQ4 2025Date3/27/2026TimeAfter Market ClosesConference Call DateFriday, March 27, 2026Conference Call Time7:00AM ETUpcoming EarningsIntensity Therapeutics' Q2 2026 earnings is estimated for Thursday, August 6, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, August 5, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Intensity Therapeutics Earnings HeadlinesIntensity Therapeutics Inc. (NASDAQ:INTS) Receives Average Rating of "Moderate Buy" from AnalystsJuly 22, 2026 | americanbankingnews.comIntensity Therapeutics Inc. (NASDAQ:INTS) Sees Large Growth in Short InterestJuly 17, 2026 | americanbankingnews.comBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to move out of overpriced AI stocks before the tech trade breaks down and into lesser-known names with real potential to challenge the Mag 7. One pick he calls 'an upgrade to Tesla stock' is a little-known company that just inked a partnership with Nvidia, positioning it ahead of Tesla in the autonomous vehicle race.July 28 at 1:00 AM | Chaikin Analytics (Ad)Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study)July 15, 2026 | prnewswire.comIntensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6July 1, 2026 | prnewswire.comIntensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical AwardMay 14, 2026 | prnewswire.comSee More Intensity Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Intensity Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Intensity Therapeutics and other key companies, straight to your email. Email Address About Intensity TherapeuticsIntensity Therapeutics (NASDAQ:INTS), Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.View Intensity Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles AMD’s AI Bubble Could Burst Into Explosive UpsideRefiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There?Atlassian’s AI Pivot Is Starting to Challenge Wall Street’s Bear CaseVerizon May Be an AI Infrastructure Stock Hiding in Plain SightApple’s Earnings Setup Puts Its Record Rally and AI Patience to the TestWintrust: A Quiet Regional Bank Posting Loud ResultsMarketBeat Week in Review – 07/20- 07/24 Upcoming Earnings Agnico Eagle Mines (7/29/2026)General Dynamics (7/29/2026)L3Harris Technologies (7/29/2026)Automatic Data Processing (7/29/2026)Amphenol (7/29/2026)ARM (7/29/2026)Fortinet (7/29/2026)Lam Research (7/29/2026)Meta Platforms (7/29/2026)Microsoft (7/29/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
